Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wooree Choi

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Genomics & Informatics|January 3, 2019
Multi-block Analysis of Genomic Data Using Generalized Canonical Correlation AnalysisInyoung Jun, Wooree Choi, Mira Park
Advances in Therapy|January 9, 2023
Safety and Effectiveness of SB2 (Infliximab Biosimilar) in Adult Patients with Immune-Mediated Inflammatory Diseases: A Post-Marketing Surveillance in KoreaDong W Kim, Yousun Lee, Geuntae Kim, et al.
BMJ Open Ophthalmology|December 19, 2023
Biosimilar SB15 versus reference aflibercept in neovascular age-related macular degeneration: 1-year and switching results of a phase 3 clinical trialSriniVas R Sadda, Mario Bradvica, Attila Vajas, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Genomics & Informatics|January 3, 2019
Multi-block Analysis of Genomic Data Using Generalized Canonical Correlation AnalysisInyoung Jun, Wooree Choi, Mira Park
Advances in Therapy|January 9, 2023
Safety and Effectiveness of SB2 (Infliximab Biosimilar) in Adult Patients with Immune-Mediated Inflammatory Diseases: A Post-Marketing Surveillance in KoreaDong W Kim, Yousun Lee, Geuntae Kim, et al.
BMJ Open Ophthalmology|December 19, 2023
Biosimilar SB15 versus reference aflibercept in neovascular age-related macular degeneration: 1-year and switching results of a phase 3 clinical trialSriniVas R Sadda, Mario Bradvica, Attila Vajas, et al.
Pageof 1